Phase II/III study of Alzheimer’s drug exceeds enrollment expectations

  • Annovis Bio shares rise 13% after full enrollment reached for Buntanetap study
  • Phase II/III study of buntanetap for Alzheimer’s Disease exceeds full enrollment
  • Stock hits 52-week low of $5.42 on Nov. 8, down 45% in the past 12 months
  • Over 700 patients screened and 353 patients enrolled across 54 sites in the U.S.
  • Study investigates efficacy, safety, and tolerability of buntanetap in mild to moderate Alzheimer’s patients
  • Data from the study expected by the end of March 2024

Annovis Bio shares have surged 13% to $7.32 following the announcement that the company’s phase II/III study for its lead compound, buntanetap, in Alzheimer’s Disease has successfully achieved full enrollment. This positive development comes after the stock hit a 52-week low of $5.42 on November 8, representing a 45% decline over the past year. The study, which began in March, has screened over 700 patients and enrolled a total of 353 patients across 54 sites in the United States. It is a randomized, double-blind trial that aims to assess the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate Alzheimer’s. Participants receive either one of three doses of buntanetap or a placebo in addition to their standard care for a duration of 12 weeks. Annovis Bio anticipates having data from this study available by the end of March 2024.

Public Companies: Annovis Bio (N/A)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides specific information about Annovis Bio’s phase II/III study of buntanetap for Alzheimer’s Disease, including enrollment numbers and study details. It also mentions the stock performance and the expected timeline for data availability. The information provided appears to be factual and does not contain any obvious bias or misleading statements.

Noise Level: 7
Justification: The article provides some relevant information about Annovis Bio’s phase II/III study of buntanetap for Alzheimer’s Disease, including enrollment numbers and the expected timeline for data availability. However, it lacks scientific rigor and intellectual honesty as it does not provide any analysis or evidence to support the efficacy, safety, or tolerability of buntanetap. Additionally, it does not explore the consequences of the study results on patients or the potential impact on the company’s stock price. Overall, the article contains some relevant information but lacks depth and critical analysis.

Financial Relevance: Yes
Financial Markets Impacted: Annovis Bio shares

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to a financial topic as it discusses the stock performance of Annovis Bio and the results of their phase II/III study for Alzheimer’s Disease. However, there is no mention of an extreme event or its impact.

Reported publicly: www.marketwatch.com